Based in Lund, Ideon Science Park, Sweden, BioInvent has approximately 94 full-time employees. We pride ourselves on providing a supportive team structure and offering numerous opportunities for staff from different departments to work together, sharing knowledge and learning from each other.
Our future as a dynamic organisation is largely dependent on the knowledge, creativity and skills of our employees. As a relatively small organisation, we have an informal and flexible work environment, providing numerous opportunities for professional and personal development.
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow on Twitter: @BioInvent.